Form 4: Adaptimmune Therapeutics COO Sells Shares to Cover Tax Obligations

William C. Bertrand Jr., Chief Operating Officer of Adaptimmune Therapeutics PLC, sold American Depositary Shares (ADS) to cover tax obligations related to the exercise of vested RSU-style share options.

Summary

• William C. Bertrand Jr., the Chief Operating Officer of Adaptimmune Therapeutics PLC, filed a Form 4 detailing changes in beneficial ownership.
• The transactions involved the sale of American Depositary Shares (ADS) representing ordinary shares of the Issuer.
• These sales were executed on January 13, 2025, and January 15, 2025, at weighted average prices of $0.5879 and $0.5748, respectively.
• The sales were conducted to cover tax withholding obligations and associated sale costs related to the exercise of vested RSU-style share options.
• The ADSs were obtained from the exercise of approximately 25% of RSU-style share options granted on January 11, 2021, January 12, 2022 and January 15, 2024.
• Following these transactions, Bertrand directly holds 13,756 ADSs and indirectly holds options covering an aggregate of 13,500,558 ordinary shares of the Issuer.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock option exercises and sales for tax purposes, indicating a neutral sentiment.

Industry Context

Sales of shares to cover tax obligations upon the exercise of stock options are a routine practice among corporate executives and do not necessarily indicate a lack of confidence in the company's future prospects.

Stakeholder Impact

• The sale of shares by the COO may have a minor, temporary impact on shareholders due to the increased supply of shares in the market.

Key Dates